Giorgio Sandrini, Armando Perrotta, Cristina Tassorelli, Giuseppe Nappi

Research output: Contribution to journalArticlepeer-review


Migraine is a multifactorial chronic central nervous system disorder, characterized by recurrent disabling attacks of moderate-to-severe headache. Symptomatic acute treatment of migraine should provide rapid and effective relief of the headache pain. The introduction of the 5-HT1B/1D receptor agonists (triptans) expanded the armamentarium for acute migraine pain treatment. Eletriptan is a second-generation triptan with favorable bioavailability and half-life, a high affinity for 5-HT1B/1D receptors and selectivity for cranial arteries. Eletriptan (40 and 80 mg) has been shown to be effective as early as 30 min after administration and well tolerated when compared to placebo. In comparative clinical trials, eletriptan 40 and 80 mg were superior or equivalent to other triptans and have shown a very high safety and tolerability profile across the studies performed. Eletriptan showed the most favorable cost-effectiveness profile when compared with other agents in its class.

Original languageEnglish
Pages (from-to)1587-1598
Number of pages12
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number12
Publication statusPublished - Dec 2009


  • Eletriptan
  • Migraine
  • Serotonin agonists
  • Triptans

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology


Dive into the research topics of 'Eletriptan'. Together they form a unique fingerprint.

Cite this